Exelixis, Inc. (EXEL) CEO Mike Morrissey on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/11/22
Exelixis Announces First Quarter 2022 Financial Results and Provides Corporate UpdateBusiness Wire • 05/10/22
Exelixis' Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid CancerBusiness Wire • 05/03/22
Exelixis to Release First Quarter 2022 Financial Results on Tuesday, May 10, 2022Business Wire • 04/26/22
Exelixis Announces Initiation of First-In-Human Phase 1 Trial Evaluating XL114 Monotherapy in Patients with Non-Hodgkin's LymphomaBusiness Wire • 04/14/22
Exelixis' Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid CancerBusiness Wire • 03/25/22
Exelixis Announces Final Overall Survival Results from Phase 3 COSMIC-312 Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver CancerBusiness Wire • 03/14/22